RxDoctor Payments Data

Sugat Patel, MD

Retina Specialist · Dublin, OHNPI 1831288448

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $21,845 of the $33,300 with a category attached, or 65.6%. US Retina LLC accounts for 65.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $10,889 and has fallen 71.3% since, to $3,125 in 2025.

$33,300in general payments, 2019–2025

Across 276 payments — averaging $120.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$22K
  • Genentech USA, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Onmark, Inc.$2K
  • Alimera Sciences, Inc.$1K
  • AbbVie$1K
  • plus $4K from 22 others
$1,183,400in research payments, 2019–2025

Across 319 payments — averaging $3709.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$537K
  • Bayer$309K
  • Regeneron$251K
  • Novartis$67K
  • AbbVie$20K

What the payments were for

  • Travel & lodging$8863%
  • Food & beverage$10,53432%
  • Education$170%
  • Gifts$170%
  • Ownership interest$21,84566%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,300 in reported general payments places this provider in the 80th percentile of 69 retina specialist providers in Ohio.

See all retina specialist providers in Ohio

Medicare billing

Part B allowed, 2024
$2,784,767
Medicare patients
991
Services billed
23,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate236$6,582
Atropine Sulfate89$2,461
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha176$1,770
Timolol Maleate182$1,383
Ketorolac Tromethamine70$1,045
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$460
Brimonidine Tartrate68$441
Dorzolamide Hcl17$357

Paid to pharmacies, not to this prescriber.

Other retina specialist in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →